| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Breast Medical Oncology, 2 Molecular and Cellular Oncology, and 3 Bone Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody directed against HER-2. The objective response rate to trastuzumab monotherapy is 12–34% for a median duration of 9 months, by which point most patients become resistant to treatment. We created two trastuzumab-resistant (TR) pools from the SKBR3 HER-2-overexpressing breast cancer cell line to study the mechanisms by which breast cancer cells escape trastuzumab-mediated growth inhibition. Both pools maintained her-2 gene amplification and protein overexpression. Resistant cells demonstrated a higher S-phase fraction by flow cytometry and a faster doubling time of 24–36 h compared with 72 h for parental cells. The cyclin-dependent kinase inhibitor p27kip1 was decreased in TR cells, and cyclin-dependent kinase 2 activity was increased. Importantly, exogenous addition of p27kip1 increased trastuzumab sensitivity. Additionally, resistant cells displayed heightened sensitivity to the proteasome inhibitor MG132, which induced p27kip1 expression. Thus, we propose that trastuzumab resistance may be associated with decreased p27kip1 levels and may be susceptible to treatments that induce p27kip1 expression.
This article has been cited by other articles:
|
|
 |
|
  D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, and R. M. Reilly Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate J. Nucl. Med., September 1, 2008; 49(9): 1498 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Rowe, T. Ozbay, L. M. Bender, and R. Nahta Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer Mol. Cancer Ther., July 1, 2008; 7(7): 1900 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ravaioli, F. Monti, M. M. Regan, F. Maffini, M. G. Mastropasqua, V. Spataro, M. Castiglione-Gertsch, I. Panzini, L. Gianni, A. Goldhirsch, et al. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer Ann. Onc., April 1, 2008; 19(4): 660 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nahta, L. X.H. Yuan, Y. Du, and F. J. Esteva Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Mol. Cancer Ther., February 1, 2007; 6(2): 667 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cardoso, V. Durbecq, J.-F. Laes, B. Badran, L. Lagneaux, F. Bex, C. Desmedt, K. Willard-Gallo, J. S. Ross, A. Burny, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner Mol. Cancer Ther., December 1, 2006; 5(12): 3042 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-H. Tseng, Y.-C. Wang, S.-C. Weng, J.-R. Weng, C.-S. Chen, R. W. Brueggemeier, C. L. Shapiro, C.-Y. Chen, S. E. Dunn, M. Pollak, et al. Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor Mol. Pharmacol., November 1, 2006; 70(5): 1534 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jerome, N. Alami, S. Belanger, V. Page, Q. Yu, J. Paterson, L. Shiry, M. Pegram, and B. Leyland-Jones Recombinant Human Insulin-like Growth Factor Binding Protein 3 Inhibits Growth of Human Epidermal Growth Factor Receptor-2-Overexpressing Breast Tumors and Potentiates Herceptin Activity In vivo. Cancer Res., July 15, 2006; 66(14): 7245 - 7252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Swanton, A. Futreal, and T. Eisen Her2-targeted therapies in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4377s - 4383s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nahta, L. X.H. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells Cancer Res., December 1, 2005; 65(23): 11118 - 11128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Springett, L. Bonham, A. Hummer, I. Linkov, D. Misra, C. Ma, G. Pezzoni, S. Di Giovine, J. Singer, H. Kawasaki, et al. Lysophosphatidic Acid Acyltransferase-{beta} Is a Prognostic Marker and Therapeutic Target in Gynecologic Malignancies Cancer Res., October 15, 2005; 65(20): 9415 - 9425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 Clin. Cancer Res., September 1, 2005; 11(17): 6382 - 6389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells Cancer Res., August 1, 2005; 65(15): 6891 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, L. Vellon, and R. Lupu Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene Ann. Onc., August 1, 2005; 16(8): 1253 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma J. Clin. Pathol., May 1, 2005; 58(5): 500 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Menendez, L. Vellon, and R. Lupu Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors? Experimental Biology and Medicine, March 1, 2005; 230(3): 151 - 154. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification Ann. Onc., March 1, 2005; 16(3): 359 - 371. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
